Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

OTC labeling exemption

This article was originally published in The Tan Sheet

Executive Summary

Zee Medical should implement asterisk notations for over-inclusive inactive ingredient listing for company's PainAid Pain Relief Tablets, FDA tells firm in Dec. 10 letter. In November 1999, Zee was granted FDA permission to use phrase "may contain" to list inactive ingredients. However, in November 2001 responses to citizen petitions filed by an Atlanta law firm and CHPA, agency said manufacturers should, instead, use phrase "contains one or more of these ingredients" and place asterisks next to inactives that may or may not appear in the product (1"The Tan Sheet" Nov. 12, 2001, p. 4)...

You may also be interested in...



OTC Inactive Ingredient Labeling Guidance To Be Issued By FDA

FDA plans to issue a guidance to industry on how to list inactive ingredients that may or may not be present in OTC drug labeling

Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says

The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.

The Aspirin Test For AI?

US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093472

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel